Cycle 1 2017 Funding Cycle

PCORI Funding Announcement Reopened:
Comparison of Surgical and Nonsurgical Options for Management of Nonspecific Chronic Low Back Pain

Published January 17, 2017

This PCORI Funding Announcement (PFA) applies to the funding cycle that closes on May 17, 2017, at 5 p.m. (ET). Application Guidelines, templates, and other resources are available at http://www.pcori.org/Cycle-1-2017-surgical-options-low-back-pain.
About PCORI

The Patient-Centered Outcomes Research Institute (PCORI) is committed to transparency and a rigorous stakeholder-driven process that emphasizes patient engagement. PCORI uses a variety of forums and public comment periods to obtain public input to enhance its work. PCORI helps people make informed healthcare decisions and improves healthcare delivery and outcomes by producing and promoting high-integrity, evidence-based information that comes from research guided by patients, caregivers, and the broader healthcare community.

PCORI was authorized by Congress in 2010 as a nonprofit, nongovernmental organization. PCORI’s purpose, as defined by our authorizing legislation, is to help patients, clinicians, purchasers, and policymakers make better-informed health decisions by “advancing the quality and relevance of evidence about how to prevent, diagnose, treat, monitor, and manage diseases, disorders, and other health conditions.”

Patient-Centered Outcomes Research Institute
1828 L St., NW, Suite 900
Washington, DC 20036
Phone: 202-827-7700
Fax: 202-355-9558
Email: info@pcori.org

Follow us on Twitter: @PCORI
Overview

<table>
<thead>
<tr>
<th>Published</th>
<th>January 17, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Letter of Intent Due</td>
<td>February 14, 2017 by 5 p.m. (ET)</td>
</tr>
</tbody>
</table>

Letters of Intent (LOIs) will be screened for responsiveness to this PCORI Funding Announcement (PFA) and fit to program goals. Only those applicants selected will be permitted to submit full applications. Notification of denial or approval to submit a full application will occur no later than March 15, 2017.

Summary

The Patient-Centered Outcomes Research Institute (PCORI) seeks to fund pragmatic clinical trials that compare optimized surgical and nonsurgical options for management of nonspecific chronic low back pain. The research is expected to examine treatment options, as well as systems-level interventions or those aimed at eliminating health or healthcare disparities.

Proposed studies must address clinical and healthcare delivery choices faced by patients, their caregivers, clinicians, or delivery systems. Proposed studies must compare two or more active interventions that have been shown to be effective. They must involve patient populations that represent the U.S. population; be large enough to provide precise estimates of hypothesized effectiveness differences; and be large enough to support evaluation of potential differences in treatment effectiveness and/or harms among groups of patients defined by clinical, sociodemographic, or other characteristics.

For this solicitation, applicants should document that they have consulted with patients and other stakeholders to identify the important decisional dilemmas that drove development of the research questions and proposed research approach (or reference previously documented decisional dilemmas); proposed research should address known evidence gaps identified through systematic review. Although PCORI does not require that relevant national patient organizations, professional organizations, and payer or purchaser organizations be formally included as partners and active participants prior to contract award, successful applicants may be required to develop such formal arrangements. PCORI may require a project Study Advisory Committee (SAC)¹ that is comprised of national or regional organizations that represent—at a minimum—patients and families with lived experience, relevant clinicians, payers, and health plans. Scientific and methodological experts may also be recommended for this oversight role. The SAC advises and assists the research team with refining the study questions, outcomes, and protocol. PCORI expects applications to follow the randomized controlled trial (RCT) study design specified for the research question. Note that this funding program does not support applications to conduct cost-effectiveness analysis, systematic reviews, or development and evaluation of shared decision making or decision-support tools.

The proposed studies must address the priority research question identified in the main body of the PFA.

¹ The intent of the SAC described in the PFA is to ensure that a broad spectrum of stakeholders and patients advise and assist the research team with refining the study questions, outcomes, and protocols. These stakeholders and patients must include national or regional organizations that represent—at a minimum—patients or families with lived experience; relevant clinicians; payers; and health plans. Additional representation may be recommended in collaboration with PCORI, including individual patients with lived experience and other relevant stakeholders, such as scientific and methodological experts. However, PCORI understands that engagement structures and approaches vary widely. Other engagement approaches, such as forming stakeholder groups, panels, task forces, working groups, and other bodies—or involving individual patient and stakeholder partners in various ways—are also permissible to employ (either in addition to or instead of) the formation of the SAC. The SAC provision is not meant to require that a separate governance or advisory entity be established beyond the study governance and advisory structure the awardee has planned, if an applicant already has an approach for including the relevant and required stakeholders and patient partners. For clarification in your application materials and merit review purposes, please indicate which body or structure is filling the SAC requirements, including the requirements for in-person meetings at least two times per year and appropriate budgeting.

PCORI Cycle 1 2017 Funding Announcement: Comparison of Surgical and Nonsurgical Options for Management of Nonspecific Chronic Low Back Pain
PCORI Cycle 1 2017 Funding Announcement: Comparison of Surgical and Nonsurgical Options for Management of Nonspecific Chronic Low Back Pain

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Key Dates</strong></td>
<td><strong>Maximum Project Budget (Total Direct Costs)</strong>: $15 million</td>
</tr>
<tr>
<td></td>
<td><strong>Maximum Project Period</strong>: Five years</td>
</tr>
<tr>
<td></td>
<td><strong>Funds Available Up To</strong>: $22 million</td>
</tr>
<tr>
<td></td>
<td><strong>Eligibility</strong></td>
</tr>
<tr>
<td></td>
<td>Applications may be submitted by any private-sector research organization, including any nonprofit or for-profit organization; any public-sector research organization, including any university or college hospital or healthcare system, laboratory, or manufacturer; or any unit of local, state, or federal government. The Internal Revenue Service must recognize all U.S. applicant organizations. Nondomestic components of organizations based in the United States and foreign organizations may apply as long as there is demonstrable benefit to the U.S. healthcare system and U.S. efforts in the area of patient-centered research can be clearly shown. Organizations may submit multiple applications for funding. Individuals are not permitted to apply.</td>
</tr>
<tr>
<td></td>
<td><strong>Review Criteria</strong></td>
</tr>
<tr>
<td></td>
<td>1. Potential for the study to fill critical gaps in evidence</td>
</tr>
<tr>
<td></td>
<td>2. Potential for the study findings to be adopted into clinical practice and improve delivery of care</td>
</tr>
<tr>
<td></td>
<td>3. Scientific merit (research design, analysis, and outcomes)</td>
</tr>
<tr>
<td></td>
<td>4. Investigator(s) and environment</td>
</tr>
<tr>
<td></td>
<td>5. Patient-centeredness</td>
</tr>
<tr>
<td></td>
<td>6. Patient and stakeholder engagement</td>
</tr>
<tr>
<td></td>
<td><strong>Contact Us</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Programmatic Inquiries</strong>: Contact the PCORI Helpdesk via email (<a href="mailto:sciencequestions@pcori.org">sciencequestions@pcori.org</a>) or phone (202-627-1884), or complete the Research Inquiry Form (<a href="http://www.pcori.org/content/research-inquiry">http://www.pcori.org/content/research-inquiry</a>). PCORI will provide a response within three business days. However, we cannot guarantee that all questions will be addressed in a timely fashion when the inquiry is made three or fewer business days before an LOI or application deadline.</td>
</tr>
<tr>
<td></td>
<td><strong>Administrative, Financial, or Technical Inquiries</strong>: Contact the PCORI Helpdesk at <a href="mailto:pfa@pcori.org">pfa@pcori.org</a>. PCORI will provide a response within two business days. Note that during the week of the application deadline, response times may exceed two business days. One week before an application deadline, applicants may also call the PCORI Helpdesk (202-627-1885). Applicants are asked to plan accordingly. It is the applicant’s responsibility to submit the application on or before the application deadline.</td>
</tr>
<tr>
<td></td>
<td><strong>Other</strong></td>
</tr>
<tr>
<td></td>
<td>*Deadlines are at 5 p.m. (ET). If a deadline falls on a weekend or federal holiday, the deadline will be the following Monday or the next day after the federal holiday.</td>
</tr>
</tbody>
</table>
What’s new for Cycle 1 2017:
- New Criterion 4 added and updated Section IV Merit Review
- Replication and Reproducibility of Research and Data-Sharing Plan section has been replaced with the Data Management and Data-Sharing Plan
- Includes links to new PCORI Policy on Data and Safety Monitoring Plans for PCORI-Funded Research and Process for Peer Review of Primary Research and Public Release of Research Findings

This PFA is a reissue of the Cycle 2 2016 Comparison of Surgical and Nonsurgical Options for Management of Nonspecific Chronic Low Back Pain. The contents have been modified and require close attention to important differences, including the following:
- Additional details about the nonsurgical comparator
- Additional guidance about the use of the pragmatic-explanatory continuum for the purposes of this funding announcement
Table of Contents

I. Introduction ..................................................................................................................... 1
   Summary of Program ........................................................................................................ 1
   Background ..................................................................................................................... 2
   Research Topic Prioritization .......................................................................................... 4
   Priority Research Question .............................................................................................. 4
   Funds Available ............................................................................................................... 6

II. Guidance for Preparing Applications ............................................................................ 7
   Specific Requirements .................................................................................................... 7
   Nonresponsiveness .......................................................................................................... 9
   Features of Patient-Centered Outcomes Research (PCOR) ............................................. 10
   Leveraging Existing Resources ..................................................................................... 10
   Preliminary Data and Use of Accepted Measures .......................................................... 10
   Methodological Considerations ..................................................................................... 10
   Patient and Stakeholder Engagement .......................................................................... 11
   Populations Studied ....................................................................................................... 12
   Budget and Duration of Project ...................................................................................... 13
   Collaboration .................................................................................................................. 14
   Protection of Human Subjects ....................................................................................... 14
   Required Education of Key Personnel on the Protection of Human Subject Participants .... 15
   Data Management and Data-Sharing Plan .................................................................... 15
   Peer Review and Release of Research Findings ............................................................. 15

III. How To Submit an Application .................................................................................... 15
   Letter of Intent ................................................................................................................ 15
   Letter of Intent Review ................................................................................................... 16
   Submission Dates ............................................................................................................ 17
   PCORI Online System ..................................................................................................... 17
   Applicant Resources ....................................................................................................... 17

IV. Merit Review ............................................................................................................... 17
   Preliminary Review ......................................................................................................... 18
   In-Person Review ............................................................................................................ 21
PCORI Cycle 1 2017 Funding Announcement: Comparison of Surgical and Nonsurgical Options for Management of Nonspecific Chronic Low Back Pain
I. Introduction

Summary of Program

The Patient-Centered Outcomes Research Institute (PCORI) is launching this funding initiative to support patient-centered comparative clinical effectiveness research (CER) that addresses important questions about the comparison of surgical and optimized nonsurgical options for managing nonspecific chronic low back pain. Through this PCORI Funding Announcement (PFA), PCORI seeks to fund pragmatic clinical trials with a sufficient sample size to address the research question. This program’s goal is to generate valid clinical evidence that is readily generalizable to the broader population of people with chronic nonspecific low back pain. A similar PFA had been released in April 2016. This announcement replaces that version. Please carefully review the current announcement, which includes some changes in the descriptions of the clinical interventions and comparators of interest.

The definition of this clinical condition is low back pain on at least 50 percent of days in the past six months, unaccompanied by pain or neurological symptoms and signs in the lower legs, and without abnormalities on imaging tests other than degenerative disc disease. This population includes those individuals who have progressed from a period of intermittent episodes of low back pain to the state of persistent pain on at least half of the days. Such people often have undergone various types of pharmacological treatments, such as anti-inflammatory or pain medications and various types of physical interventions, such as physical therapy, exercise programs, or spinal manipulation. They also may have participated in programs using psychological approaches to pain management. For the purposes of this PFA, the population does not include those individuals who have undergone previous surgical procedures to treat low back pain.

Applications must address the priority research question described in this PFA. The proposed study should also:

- Include patients with chronic nonspecific low back pain who are representative of the population faced with choosing between the proposed study interventions.
- Take place within typical clinical care sites that perform the compared interventions.
- Have a sufficiently large study sample to estimate comparative treatment effects precisely. (When determining anticipated effect sizes, appropriate attention should be paid to basing such estimates on efficacy results observed in previous adequately-conducted clinical studies.)
- Specify clinical and other factors that will be used to define patient characteristics that are known to be associated with differential treatment response (Heterogeneity of Treatment Effect, or HTE).

---

• Compare the effectiveness\(^3\) of the study interventions for improving patient-centered outcomes for chronic low back pain and the relative side-effects or harms of treatments.

**Background**

Low back pain is a common clinical condition. As many as one quarter of adults in the United States had back pain lasting a full day during the previous three months.\(^4\) Although most episodes of low back pain are self-limited, some people have recurrent acute episodes, with periods of only minimal symptoms between these acute episodes. Some individuals then transition to a state of persistent low back pain that does not remit. This condition is known as chronic low back pain and is defined as low back pain occurring on at least half of the days in the preceding six months.\(^2\) In the United States, low back pain is the largest contributor to years lived with disability.\(^5\) An estimated 149 million workdays are lost every year in the United States due to low back pain.\(^6\) The total costs related to back pain exceed $100 billion per year in the United States, but only 5 percent of back pain patients generate 75 percent of these costs.\(^7\)

CER on chronic nonspecific low back pain has been limited by several factors, including (1) a lack of consensus on the most clinically meaningful outcomes to measure; (2) small differences, if any, between most therapies within a given category when compared with one another (e.g., various types of psychological interventions); (3) a lack of clarity in the extant literature regarding which patients respond to which therapies;\(^8\) and (4) treatment approaches that historically have primarily focused upon a biomedical model of chronic low back pain rather than a comprehensive, multidisciplinary biopsychosocial model of care.\(^9\) Because treatment options for low back pain are often aligned with different professional disciplines (e.g., acupuncture, physical therapy, spinal manipulation, and spine surgery), existing referral patterns and access to different treatments could be a barrier to diffusion of best clinical practices (especially those that require combinations of multiple or complementary treatments). Thus, insights provided by new CER could have an important clinical impact.

Surgical intervention, which includes various approaches for excising portions of lumbar intervertebral disks and fusing or fixating lumbar vertebrae, is a mode of treatment that is being used with increasing frequency in the United States to manage chronic low back pain. Some patients have clearly defined anatomic conditions (defined by imaging studies and patterns of symptoms) that make them the most

---

\(^3\) “Effectiveness” is the extent to which an intervention does more good than harm in a broad mix of patients when provided under the usual circumstances of healthcare practice (modified from ec.europa.eu/enterprise/sectors/healthcare/files/docs/rea_principles_en.pdf).


suitable candidates for surgical procedures. Previous multi-center clinical trials have found that such patients attain modest benefits from surgery. However, many other patients who have less well-defined anatomic conditions also receive surgery. The annual rate of lumbar fusion surgery increased almost threefold from 1988 to 2008. A 2007 systematic review by Mirza and Deyo summarized four randomized trials comparing lumbar fusion surgery with noninvasive interventions. The pooled effect size was four points on the Oswestry Disability Index (1–100), indicating that the average clinical benefit, if any, is small. However, methodological problems made it difficult to discern whether there was a clear benefit of surgery over the nonsurgical approaches examined. Despite inconclusive findings on the efficacy of lumbar fusion over nonsurgical approaches for chronic nonspecific low back pain, the surgery has proliferated, and there has been an insufficient body of research examining the appropriateness of lumbar fusion for this indication.

It remains unclear which patients may be most likely to achieve greater benefit from surgical or comprehensive multidisciplinary nonsurgical interventions. Optimized multidisciplinary nonsurgical interventions have not been subjected to definitive comparisons with surgery, possibly due to these treatments being unavailable or difficult to access. Most of the current randomized controlled trials (RCTs) in chronic nonspecific low back pain are small and inconclusive.

In the absence of good clinical evidence on this question, there is a need for new research that directly compares surgical and optimized comprehensive multidisciplinary nonsurgical treatment approaches for people with chronic nonspecific low back pain. As of January 2016 the clinicaltrials.gov trial registry lists 122 open studies of interventions for chronic low back pain. None of them are randomized trials comparing lumbar fusion surgery with nonsurgical interventions.

Identifying the appropriate interventions and comparators for a new large-scale comparative clinical effectiveness study should be based on the types of surgical and nonsurgical treatments found to be most efficacious and equally applicable to the population in question. Comparing surgical and nonsurgical treatments that are most commonly in use is a justifiable strategy if investigators can provide assurance that the nonsurgical intervention is sufficiently robust to allow a non-biased comparison with surgical outcomes. A review of current rates of orthopedic procedures for patients with chronic low back pain indicates that fusion procedures are most commonly used. Under this PFA, a proposed study should include fusion surgery as one of the treatment options for comparison.

A recent systematic review commissioned by the Agency for Healthcare Research and Quality addressed nonsurgical treatment options for managing chronic low back pain. This review examined a wide range of treatment approaches. It found that there is moderately strong evidence of efficacy for several different single-treatment modalities when compared with patients receiving no interventions.

---


These single interventions include exercise, yoga, acupuncture, massage, and psychological therapies (including cognitive behavioral approaches). However, there is also moderately strong evidence showing that multidisciplinary interventions for chronic low back pain are superior to monotherapies in this patient population. Under this PFA, proposed studies should include a comparison group that receives nonsurgical treatment that is comprehensive, multidisciplinary, and justified on the basis of convincing empirical or clinical evidence regarding its component interventions, which should be appropriately individualized and address multiple mechanisms for managing chronic low back pain. Applicants should address and justify how the proposed interventions being compared will balance clinical fidelity with adaptations occurring due to patient factors and local providers’ implementation practices.

Research Topic Prioritization

PCORI’s multi-stakeholder Advisory Panel for the Assessment of Prevention, Diagnosis, and Treatment Options rated chronic nonspecific low back pain as a high-priority topic. PCORI then hosted a multi-stakeholder workgroup to develop research questions focusing on the comparative clinical effectiveness of treatments for this patient population. On June 9, 2015, 16 participants representing patients, clinicians, researchers, payers, and purchasers met for a one-day workshop. The meeting was open to the public via teleconference, with slides and meeting materials posted on the PCORI website. Throughout the day, discussions centered around questions submitted by stakeholders and around defining the study population, interventions, and outcome measures.

Subsequently, PCORI met individually with representatives of five professional organizations that represent clinicians who specialize in spine conditions, including nonspecific chronic low back pain (spine surgeons, orthopedic surgeons, neurosurgeons, physical therapists, and primary care physicians). The clinicians consistently described chronic nonspecific low back pain as a heterogeneous condition for which they lacked evidence regarding factors associated with response to treatment. To address this problem, PCORI convened a second multi-stakeholder meeting that took place on January 8, 2016. The meeting focused on identifying clinical characteristics that predict how well chronic nonspecific low back pain patients respond to surgery and nonsurgical interventions. The multi-stakeholder panel suggested a number of predictors of response to treatment for exploration (e.g., obesity, current or past use of chronic opioid therapy or history of substance abuse, presence of chronic pain in other sites, mental health conditions, etc.).

Priority Research Question

Applications should propose RCTs that address the priority research question noted below. The study design should maximize the applicability of the study’s results in the settings in which patients typically decide between the interventions that the trial compares. The studies should be conducted in such settings. The studies must be relatively large, in part to be able to demonstrate differences in comparative clinical effectiveness in the study arms as randomized, but also to allow adequate power to detect the potential differences in treatment responses by patient clinical and other characteristics. In considering pragmatic approaches to their study design, conduct, and analysis, applicants should refer to

---

the multiple elements of the pragmatic-explanatory continuum and explicitly consider the tradeoffs of each element on the continuum. Absolute pragmatism is not the ideal, particularly for the standardization of interventions chosen for comparison. Interventions require some degree of flexibility in their use but must be sufficiently well-defined to be replicable in their dissemination and implementation in U.S. health care.

The priority research question is:

What is the comparative clinical effectiveness of lumbar fusion surgery versus an optimized nonsurgical comprehensive multidisciplinary program for chronic nonspecific low back pain?

PCORI expects the proposed RCT to be a two-armed study comparing lumbar fusion surgery and optimized multidisciplinary nonsurgical management strategies, with patients recruited from primary care settings. PCORI defines multidisciplinary programs as including professionals from two or more disciplines who deliver care in a coordinated fashion. Applicants should carefully address the risk of selection bias that often occurs in such surgical trials and the proposed approach to mitigate such concerns (e.g., all recruited patients complete a defined period of standard protocol-driven rehabilitation care before randomization, etc.). Given the anticipated size and scope of proposed studies submitted under this funding initiative, applications should also carefully consider and provide details supporting how the target sample size will be met across all study sites (e.g., expected eligible patient panels, recruitment capacity, integration of research and clinical workflow, etc.). The manner in which patients are randomized, assigned, referred, or otherwise become recipients of surgical and nonsurgical treatments should be thoroughly described with well-defended justification that the chosen allocation method will yield two groups of patients who are comparable and without selection or channeling biases. The elements to apply to this research question include:

- **Population/Patient Problem:** Adults with chronic nonspecific low back pain (no neurological symptoms or structural abnormalities other than disc degeneration) on at least 50 percent of days during the past six months despite current treatment (i.e., inadequate response to one or more nonsurgical treatments).

- **Intervention:** Lumbar fusion surgery. (Applicants should designate the range of specific procedures and techniques that will be included.)

- **Comparator:** An optimized, comprehensive multidisciplinary nonsurgical approach to manage chronic low back pain. Components of the multidisciplinary approach must be evidence-based, and the overall package should represent the best nonsurgical alternative to lumbar fusion, with expected treatment effects that would be comparable to surgery. The package must be well defined and justified in terms of its efficacy and feasibility for dissemination and implementation within the U.S. population and healthcare system.

- **Outcome:** The National Institutes of Health (NIH) Task Force on Research Standards for Chronic Low Back Pain outcome measures (function, pain, sleep, mood, medication use, productivity, productivity, productivity).

---

and use of opioids); healthcare utilization (emergency room visits, surgery, and hospital admissions); safety (major medical complications and infections); quality of life; and both validated general and low-back-pain-specific disability measures (e.g., Oswestry Disability Index and Roland Morris Disability Questionnaire).

- **Time**: Follow-up for two years.
- **Setting**: Community practice.

PCORI is interested in receiving applications that propose to conduct direct comparisons of surgical and nonsurgical treatment regimens. Applicants should provide a convincing explanation for the relevance of a nonsurgical treatment regimen, citing convincing evidence that it represents the most relevant and well-justified comparator to surgery. PCORI is particularly interested in studies that include populations with important disparities, important comorbidities, or difficult social conditions.

### Funds Available

PCORI has allotted up to $15 million in total direct costs under this PFA to fund high-impact studies comparing surgical and nonsurgical interventions for chronic nonspecific low back pain. The proposed budget for all studies under this PFA may go up to $22 million in total costs as appropriate, depending on the specific priority research question or questions that are proposed. The maximum project period is five years.

For this solicitation, PCORI is not requiring that relevant national patient organizations, professional organizations, and/or payer or purchaser organizations be formally included as partners and active participants prior to contract award. However, applicants should document that they have consulted with patients and other stakeholders to identify the important decisional dilemmas and evidence needs that will drive development of the research questions, or refer to previously documented decisional dilemmas. Successful applicants are required to work in collaboration with PCORI staff upon award of the proposed studies to establish a project Study Advisory Committee (SAC) or other appropriate engagement body that is composed of national or regional organizations that represent—at a minimum—patients or families with lived experience, relevant clinicians, payers, and health plans. Other representation may be recommended in collaboration with PCORI, including individual patients with lived experience and other relevant stakeholders, among them scientific and methodological experts. The SAC advises and assists the research team with further refining the study questions, outcomes, and protocol.

Given the significant treatment costs associated with some interventions, the applications must specifically address—in the context of the proposed studies—the support from payers, health plans, industry sponsors, or others in covering the study interventions and non-study, protocol-related clinical costs and services rendered in the care processes. Of particular concern would be different levels of co-payment or reimbursement between two arms in a comparative study. Ideally, cost-sharing barriers will be eliminated or equalized in the study arms. If the study design does not allow for either option, the applicant should describe why and should also discuss how differences in co-payment costs will be accounted for in the design, conduct, and analysis of the study’s findings.

It is expected that project budgets and duration will vary substantially, depending on the topic and...
approach selected, needs for recruitment or primary data collection, length of follow-up, and analytic complexity. PCORI seeks efficient studies, such as those that take advantage of large populations already under observation; registries; and the supportive involvement of delivery systems or health plans to enhance recruitment, data collection, and coverage of treatment-related costs. A prolonged recruitment period is not an acceptable rationale for longer studies. Funding requests to develop or build on initial collaboration between researchers and patient/stakeholder groups are also not appropriate for this PFA.

II. Guidance for Preparing Applications

Specific Requirements

The proposed study should strive to meet the following requirements:

- Demonstrate consultation with patients and other stakeholders or their representative groups, or reference previously documented decisional dilemmas to determine if the study is answering a critical question—one that, if adequately answered, would substantially improve decision making.
- Receive endorsement by relevant patient organizations, clinician organizations, payer or purchaser consortia, and life sciences industry representatives as potentially answering a critical question, one that if adequately answered would substantially improve decision making.
- Propose a sample size that is sufficient to allow for precise estimation of hypothesized effect sizes, but not larger than necessary to test anticipated effects. The sample size must also support testing of \textit{a priori} hypotheses related to potential differences in effectiveness depending on specific clinical characteristics (HTE).
- Examine diverse populations receiving care in real-world community practice settings.
- Have strong interest from and support by host delivery systems and clinical care settings.
- Specify broad and simple, reproducible eligibility criteria that will allow wide generalization of results, while attending appropriately to any ethical concerns of excess risk in some patient subgroups.
- As applicable, compare interventions that can be implemented in real-world settings and are known to be efficacious, effective, or in common use.
- Include patient-reported outcomes (PROs) as primary outcomes, when appropriate.
- Provide preliminary evidence of the potential for efficient recruitment, high participation rates, and appropriate oversight by local or centralized Institutional Review Boards (IRBs), including plans for streamlining or waiving individual informed consent in cases of low-risk interventions. PCORI believes that the intensity of oversight and the complexity of informed consent procedures should be closely related to the degree of risk from study participation. Applicants must address this issue and should present evidence that the study will not encounter significant barriers to recruitment or participation.
• Adhere to all applicable PCORI Methodology Standards.17 The full application will require the applicant to identify the standards appropriate to the proposed study and describe how the study team plans to address each standard.

• In the case of RCTs, also adhere to current best practices (standardized inclusion or exclusion criteria; proper randomization; techniques to minimize potential for missing data; and appropriate safety monitoring, including establishment of a Data and Safety Monitoring Board [DSMB] or indication of why such a board is unnecessary).

To carry out pragmatic studies, readily adopt the findings in a real-world setting, and maximize the efficient use of resources, care must be taken to prevent these trials from becoming more complex and onerous than necessary. The applicant is encouraged to be creative and consider the following innovative strategies, as appropriate and feasible:

• Be prepared to identify and engage with major patient and stakeholder organizations that would implement study findings, as well as with existing local communities of patients and care providers to refine the research questions and study protocol, help monitor progress, and disseminate the findings.

• Consult with patients and other stakeholders on their decisional dilemma and evidence needs or reference previously documented decisional dilemmas in preparation for the submission of Letters of Intent (LOIs) and the full applications.

• Carefully describe the pertinent evidence gaps and why the project questions represent decisional dilemmas for patients; caregivers and families; and other stakeholders, including clinicians and policy makers. Similarly, applicants should document why project outcomes are especially relevant to patients, and also document meaningful endpoints for patients and their families.

• Justify why the interventions being compared are viable treatment alternatives worthy of a significant PCORI investment to elucidate the best clinical options for subgroups of patients with nonspecific chronic low back pain.

• Minimize disruption to participants’ daily routines (e.g., minimize participant visits intended solely for study assessment purposes and capture PROs during office visits, electronically or via phone).

• Design the study so that the conduct can, as seamlessly as possible, be integrated with routine clinic or office operations.

• Use efficient methods to obtain participant consent while still meeting ethical and legal requirements.

• Capitalize on the existing electronic health records and other computerized information to identify and recruit eligible patients, monitor study conduct and patient safety, and collect study

---

17 Available at pcori.org/research-we-support/research-methodology-standards/.
outcomes information.

- If data standardization and interoperability across study sites has not already been accomplished, develop methods that will enhance the standardization of data that are accessed from different electronic health record systems.

**Nonresponsiveness**

Applications will be considered nonresponsive to this PFA if the proposed research:

- Tests efficacy (or comparative efficacy) within a tight, protocol-controlled research setting (as opposed to more real-world and pragmatic CER)
- Conducts a cost-effectiveness analysis in the form of dollar-cost per quality-adjusted life-year to compare two or more alternatives
- Directly compares the costs of care between two or more alternative approaches
- Measures the relative costs of care of two or more alternative approaches as the primary criteria for choosing the preferred alternative
- Conducts studies of the natural history of disease, instrument development, pharmacodynamics, and fundamental science of biological mechanisms
- Evaluates new or existing decision-support tools. This includes developing and evaluating a decision-support or shared-decision tool or system for patients, clinicians, or both patients and clinicians
- Develops clinical prediction or prognostication tools

Applications that include studies of these issues may measure and report use of any or all health services, but may not employ direct measurements of care costs.

PCORI does have an interest, however, in studying conditions that lead to high costs to the individual or to society. Thus, PCORI is also interested in studies that do the following:

- Address cost-related issues, such as the resources needed to replicate or disseminate a successful intervention.
- Evaluate interventions to reduce health-system waste or increase health-system efficiency.

Applications that include studies of these issues without using cost-effectiveness analyses or comparing the costs of alternatives are considered responsive.

Furthermore, PCORI discourages applications in the following categories and is likely to deem them nonresponsive:

- Study of the natural history of disease
- Instrument development
- Pharmacodynamics
Fundamental science or study of biological mechanisms
- Establishing efficacy for a new clinical strategy
- Pilot studies intended to inform larger efforts
- Comparisons of patient characteristics rather than clinical strategy options

Features of Patient-Centered Outcomes Research (PCOR)

PCOR helps people and their caregivers communicate and make informed healthcare decisions, allowing their voices to be heard in assessing the value of healthcare options. This research:

- Assesses the benefits and harms of preventive, diagnostic, therapeutic, and palliative care to inform decision making, highlighting the choices that matter to people
- Is inclusive of an individual's preferences, autonomy and needs, focusing on outcomes that people notice and care about (including survival, functioning, symptoms, and health-related quality of life)
- Incorporates a wide variety of settings and diversity of participants to address individual differences and barriers to implementation and dissemination
- Directly compares clinical interventions that are generally available in the clinical settings
- Obtains stakeholder perspectives to address the burdens to individuals, availability of services, and requirements for technology and personnel

Leveraging Existing Resources

Investigators are encouraged to propose studies that leverage existing resources, such as adding PCOR to an existing large clinical trial or analyzing existing large databases that contain valuable and relevant information that may be used to answer important CER questions.

Preliminary Data and Use of Accepted Measures

PCORI encourages investigators to design their research using valid patient-centered outcomes measures and to include preliminary data that supports the proposed measures. Investigators are encouraged to consider those measures described in the Patient-Reported Outcomes Measurement Information System (PROMIS).

Methodological Considerations

Regardless of study design, applications must adhere to all relevant PCORI Methodology Standards. These include 47 individual standards that fall into 11 categories. The first five categories are cross-cutting and are relevant to most PCOR studies. Researchers should refer to all of these standards when planning and conducting their research projects. These five categories are:

- Standards for Formulating Research Questions

---

18 Available at http://nihpromis.org/.
19 Available at pcori.org/research-we-support/the-pcori-methodology-report/.

PCORI Cycle 1 2017 Funding Announcement: Comparison of Surgical and Nonsurgical Options for Management of Nonspecific Chronic Low Back Pain
• Standards Associated with Patient-Centeredness
• Standards on Data Integrity and Rigorous Analyses
• Standards for Preventing and Handling Missing Data
• Standards for Heterogeneity of Treatment Effect (HTE)

Six other standards categories will be applicable to particular study designs and methods. The standards in each of these categories should be used for guidance when they are relevant to a particular study. These categories are:

• Standards for Data Registries
• Standards for Data Networks as Research-Facilitating Infrastructures
• Standards for Causal Inference Methods
• Standards for Adaptive and Bayesian Trial Designs
• Standards for Studies of Diagnostic Tests
• Standards for Systematic Reviews

Most of these standards should be considered minimal. Additional best practices, including relevant guidelines for conducting clinical trials developed by other organizations, should be addressed in the application for PCORI funding. To help reviewers quickly identify the adherence to a particular standard, applicants must cite each PCORI Methodology Standard within their applications as the standard is being addressed. For example, when applicants describe the need for their proposed study within the Background section, they should indicate the particular standard for Identify Gaps in Evidence in parentheses, such as “(RQ-1).”

Applicants should specifically discuss their capacity to measure such factors as differential adherence to chosen treatments (or participation in intervention programs) that could create or explain apparent differences in the effectiveness of the alternative interventions being compared in clinical populations.

**Patient and Stakeholder Engagement**

PCORI encourages all applicants to outline how patients and other stakeholders will participate as partners in various phases of the proposed research. Before completing this section of the Research Strategy, applicants are encouraged to review PCORI’s Engagement Rubric, which can be found in the PCORI Funding Opportunities. Applicants should also review the PCORI Methodology Standards Associated with Patient-Centeredness and PCORI’s Sample Engagement Plans. The rubric and Sample Engagement Plans are not intended to be comprehensive or prescriptive; instead, they provide a variety of examples to incorporate engagement, where relevant, into the research process.

Applicants are expected to consult with patients and other stakeholders on their decisional dilemma and evidence needs or to reference previously documented decisional dilemmas in preparation for the

---

submission of LOIs and applications. To describe the decisional dilemma, state the specific clinical decision(s) or treatment choice(s) confronted by the decision makers and explain how the findings from the proposed research will inform those decisions. State why this decision—such as choosing a specific medication, surgical approach, or care delivery strategy to treat a condition or manage a specific population—is important to patients. Document the uncertainty patients and other stakeholders face in making this decision. Identify the patients and other stakeholders you consulted in determining that the proposed study addresses their evidentiary needs for decision making, and indicate your commitment to continue engaging them actively in the conduct of the study. Similarly, applicants should document how the project outcomes are especially relevant and meaningful endpoints to patients and other stakeholders.

For this PFA, applicants are not required to demonstrate that patients and other stakeholders are already engaged as research team members at the time an application is submitted. However, the Engagement Plan should outline how patients and other stakeholders will participate as partners in various phases of the proposed research, once awarded. Applicants should describe their plan to form a SAC, or other appropriate engagement body, to ensure that a broad spectrum of patients and other stakeholders advise and assist the research team with refining the study questions, outcomes, and protocols. These patients and other stakeholders must include national or regional organizations that represent—at a minimum—patients, caregivers, clinicians, policy makers, and other healthcare system stakeholders. Additional representation may be recommended in collaboration with PCORI, including individual patients with lived experience and other relevant stakeholders, such as scientific and methodological experts. The SAC or other appropriate engagement body should meet in person at least two times per year, and the budget should account for these engagement costs.

PCORI understands that engagement structures and approaches vary widely. Other engagement approaches, such as forming stakeholder groups, panels, task forces, working groups and other bodies or involving individual patient and other stakeholder partners in various ways, are also permissible to employ—either in addition to or instead of—the formation of the SAC. For clarification in your application materials and for merit review purposes, please indicate which body or structure is filling the SAC requirements, including the requirements for in-person meetings at least two times per year and appropriate budgeting.

**Populations Studied**

PCORI seeks to fund research that includes diverse populations with respect to age, gender, race, ethnicity, geography or clinical status, so that possible differences in CER may be examined (otherwise known as HTE). PCORI recognizes that some proposed studies may represent important PCOR opportunities, even in the absence of a broadly diverse study population. However, the burden is on the applicant in such cases to justify the study’s importance in the absence of diversity and to discuss which subgroups are most important and how they will be analyzed, including whether there will be power to examine the question of effectiveness in subgroups. PCORI is particularly interested in the inclusion of previously understudied populations for whom effectiveness information is particularly needed, such as hard-to-reach populations or patients with multiple conditions. Thus, comparisons should examine the impact of the strategies in various subpopulations, with attention to the possibility that the effects...
might differ across subpopulations. PCORI has developed the following list of priority populations to guide our research and engagement efforts:

- Racial and ethnic minority groups
- Low-income groups
- Women
- Children (age 0–17 years)
- Older adults (age 65 years and older)
- Residents of rural areas
- Individuals with special healthcare needs, including individuals with disabilities
- Individuals with multiple chronic diseases
- Individuals with rare diseases
- Individuals whose genetic makeup affects their medical outcomes
- Patients with low health literacy or numeracy and/or limited English proficiency
- Lesbian, gay, bisexual, and transgender persons
- Veterans and members of the Armed Forces and their families

**Budget and Duration of Project**

Applicants may request up to $15 million in total direct costs for a project period not to exceed five years. Note that PCORI will not cover costs for interventions that are being compared in the proposed study. (See Appendix 2 in the Application Guidelines for details.) Applicants should submit realistic budgets and timelines. For those rare circumstances in which the estimated total direct costs exceed $15 million, provide a detailed justification in your LOI that ties the extra expense to the project’s success. Not all requests for additional funds will be approved. Any request for a project period longer than five years will be denied. For further information regarding PCORI’s policies about allowable and unallowable costs, refer to Appendix 2 of the Application Guidelines.

The funding mechanism for this program is a contract. Total project funding is contingent upon successful programmatic and budget performance (e.g., meeting recruitment targets). Milestones and targets, as well as possible pilot phases for the sole purpose of assessing feasibility of recruitment, should be included in the budget and will be negotiated at the time of the award. Awardees will be expected to provide corroborating evidence to receive continual funding support. Some of the activities that will be considered during negotiations include:

- Developing a study protocol and manual of procedures for the intervention
- Assigning roles and responsibilities of members of the study team for implementing the project
- Obtaining clearances from all institutional and community partners, including IRB approvals
• Establishing a DSMB, or providing a clear description of why a DSMB is not necessary
• Executing all subcontractor agreements
• Agreeing on eligible patient populations for study recruitment
• Identifying barriers to patient recruitment in the study and addressing these barriers effectively
• Demonstrating successful recruitment during a pilot phase (if indicated)

Refer to the Application Guidelines for a list of additional PFA-specific project milestones.

**Collaboration**

PCORI is particularly interested in applications that involve community and commercial organizations that can help researchers design, implement, disseminate, and sustain effective interventions. We encourage applications that include novel collaborations with accreditation organizations, credentialing bodies, educational enterprises, patient advocacy groups, industry, professional societies, and subspecialty societies.

**Protection of Human Subjects**

This component (up to five pages) is included in the Research Plan Template. Describe the protection of human subjects involved in your proposed research. PCORI follows the Federal Policy for the Protection of Human Subjects (45 CFR part 46), including the Common Rule. For more detailed information, please see Section 5, titled “Human Subjects Research Policy,” in the Supplemental Grant Application Instructions for All Competing Applications and Progress Reports, which is issued by the U.S. Department of Health and Human Services. PCORI does not require that applicants comply with sections of this policy that refer to requirements for federal-wide assurance or that refer to standards for including women, minorities, and children. Awardees must also comply with appropriate state, local, and institutional regulations and guidelines pertaining to the use of human subjects in research.

PCORI requires awardees to ensure that there is a Data and Safety Monitoring Plan, which may include the need to appoint a DSMB, as provided in the PCORI Policy on Data and Safety Monitoring Plans for PCORI-Funded Research.

PCORI merit reviewers will examine plans for protection of human subjects in all applications and may provide comments regarding the plans (see How To Evaluate Human Subjects Protections). Reviewers’ comments on human subject research are not reflected in the overall application score, but PCORI staff might use them during potential funding negotiations. Final determinations about the adequacy of human subject protections rest with the IRB or international equivalent that has jurisdiction for the study.

The Awardee Institution, whether domestic or foreign, bears ultimate responsibility for safeguarding the rights and welfare of human subjects in PCORI-supported activities.

---

Required Education of Key Personnel on the Protection of Human Subject Participants

PCORI requires all applicants to adhere to the NIH policy on education in the protection of human subject participants in the conduct of research. This applies to all individuals listed as key personnel in the application. The policy and FAQs are available on the NIH website.26

Data Management and Data-Sharing Plan

PCORI encourages openness in research and making research data available for purposes of replication and reproducibility. Although not required to be submitted as a component of the research application, if an award is made, the awardee is required to develop and maintain a plan that addresses data management and data sharing of research project data in a manner that is appropriate for the nature of the research project and the types of research project data, and that is consistent with applicable privacy, confidentiality, and other legal requirements.

Peer Review and Release of Research Findings

PCORI has a legislative mandate to ensure the scientific integrity of the primary research it supports and to make study findings widely available and useful to patients, clinicians, and the general public within a specific time frame. Accordingly, the PCORI Board of Governors (Board) adopted the Process for Peer Review of Primary Research and Public Release of Research Findings.27

In summary, Awardee Institutions are required to submit to PCORI for peer review a draft final research report that provides the methodological details, describes the main study results, and interprets the findings in clinical or other decisional contexts. Subject matter experts; individuals with expertise on research methodology or biostatistics; and patients, caregivers, and other healthcare stakeholders will review the draft final research report. After Awardee Institutions have responded to reviewers’ comments to PCORI’s satisfaction, the report will be accepted and considered final. PCORI will then prepare a 500-word abstract summarizing the study results for patients and the general public, which the Awardee Institution will review and approve.

PCORI will post the following materials on its website no later than 90 days after the draft final research report is accepted: (1) a 500-word abstract for medical professionals; (2) a standardized summary of the study results for patients and the general public; (3) a link to the study record on ClinicalTrials.gov (as applicable); and (4) ancillary information, including conflict of interest disclosures. The final research report, along with anonymized reviewer comments, will be made publicly available on the PCORI website no later than 12 months after its acceptance, except by prior mutual agreement with the Awardee Institution.

III. How To Submit an Application

Letter of Intent

Applicants should download the Cycle 1 2017 Low Back Pain LOI Template from the PCORI Funding Opportunities. They must complete the document and convert it to a PDF with a four-page limit. All

---

references should be included as in-text citations using American Medical Association citation style. LOIs that exceed the page limit will not be reviewed. Do not upload additional documents, such as letters of endorsement or support, as part of your LOI because they are not requested at this stage. Their inclusion will result in LOI rejection without review. Please visit the PCORI Funding Opportunities for additional applicant resources, including the PFA and required templates.

Please answer all of the questions in the LOI Template. This includes the question on brief justification for the proposed cost of the study. Providing the answer, “total direct costs not to exceed $15 million” is not sufficient. Upload your document to PCORI Online. The deadline for LOI submission is February 14, 2017, by 5 p.m. (ET).

**Letter of Intent Review**

LOIs are evaluated based on the following criteria:

- Whether the proposed topic addresses the priority research question identified in this funding announcement
- Importance of the specific research question (comparison), as evidenced by critical gaps identified by clinical guidelines developers or recent relevant systematic reviews
- A size or scope sufficient enough to have a significant impact on patient outcomes or healthcare practice
- Clarity and credibility of applicants’ responses to the LOI questions, as well as their justification of the proposed study size, citing published estimates, including effect sizes, standard deviations and the need for rigorous comparative analysis of important subgroups
- Prior relevant experience
- Programmatic fit and balance, considering whether the research study question and study design are compliant with requirements in this funding announcement
- Adherence to the administrative and formatting requirements listed in the Application Guidelines, specifically the four-page limit for the LOI

Only applicants whose LOIs are deemed most responsive to this PFA will be invited to submit a full application. Notification of denial or approval to submit an application will occur no later than March 15, 2017. Please refer to the Application Guidelines for information on how to submit your LOI via PCORI Online.

You are invited to submit an application based on the information provided in the LOI. Any changes to the following require PCORI approval:

- Research question(s)
- Specific aims
- Study design
- Comparators
Principal Investigator (PI) (Contact PI and PI #2)
Institution

If you need to change any of this information or have any questions, please email pfa@pcori.org.

Note: A PI can only submit one LOI per PFA. However, an individual listed as a PI on one LOI may be listed as and serve in another role (e.g., co-investigator or consultant) on other LOIs within the same PFA during the same cycle. A PI can submit multiple LOIs to different program PFAs in a cycle, but the PI must ensure that the research topics and projects are not similar. If a PI submits an LOI to multiple program PFAs, LOIs that exhibit scientific overlap or that appear to be duplicate submissions will be disqualified. PCORI will contact the PI and provide him or her with an opportunity to choose which PFA he or she would like to apply to. This applies to single and dual-PI submissions.

Submission Dates
LOIs and applications must be submitted in accordance with the published dates and times listed in the Overview section of this PFA and in the PCORI Funding Opportunities.28

PCORI Online System
To submit an application, you must register with PCORI Online29 and submit both an LOI and an application for each cycle in which you are applying.

Applicant Resources
PCORI Funding Opportunities http://www.pcori.org/Cycle-1-2017-Surgical-Options-Low-Back-Pain
PCORI Online System https://pcori.force.com/engagement
PCORI Funding Awards pcori.org/pfaawards

IV. Merit Review

PCORI’s merit review process is designed to support the following goals:

- Identify applications that have the strongest potential to help patients, caregivers, clinicians, policy makers, and other healthcare system stakeholders make informed decisions to improve patient outcomes.
- Implement a transparent, fair, objective, and consistent process to identify these applications.
- Elicit high-quality feedback that reflects a diversity of perspectives to ensure that the PCORI-funded research reflects the interests and views of patients and other stakeholders and those who care for them, and that it meets the criteria for scientific rigor.

---

28 Available at pcori.org/apply.
29 Available at https://pcori.force.com/engagement.
- Fund projects that fill important evidence gaps and have strong implementation potential.
- Regularly evaluate and continually improve the merit review process and policies in support of PCORI’s mission.

PCORI merit review is a multiphase process that includes PFA development; staff evaluation of LOIs; the review panel’s preliminary review of full applications; an in-person panel discussion of a subset of full applications (identified by PCORI’s Research Priority Area Program staff and based on the preliminary review and program priorities); the Selection Committee’s recommendation of applications for funding; and, finally, Board award approval.

**Preliminary Review**

PCORI conducts rigorous merit review of the full applications it receives. Note that PCORI may eliminate applications from the review process for administrative or scientific reasons (e.g., nonresponsiveness). An application may be administratively withdrawn if it is incomplete; submitted past the stated due date and time; or does not meet the formatting criteria outlined in the Application Guidelines, in the PCORI templates, and in PCORI Online. An application can be scientifically withdrawn if it is not responsive to the guidelines described in this PFA, describes research that is not comparative, includes a cost-effectiveness analysis, or otherwise does not meet PCORI programmatic requirements.

PCORI Merit Review Officers (MROs) recruit each panel based on the number of and topic areas represented by invited LOIs. MROs recruit the panel chair, scientist reviewers who are subject matter experts, patient representatives, and representatives of other stakeholder groups. All panel members receive training during the review cycle to ensure that they understand the programmatic and organizational goals of review.

The table below is designed to help applicants understand how the PCORI merit review criteria align with criteria from other funding organizations with which applicants might be familiar (e.g., NIH). Though PCORI’s criteria do map to most NIH criteria, there are areas where we ask for different information (i.e., PCORI does not include a criterion that tracks to NIH’s innovation criterion, but does include criteria evaluating patient-centeredness and engagement) reflecting PCORI’s unique approach.

<table>
<thead>
<tr>
<th>Crosswalk of PCORI Merit Review Criteria with NIH Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIGNIFICANCE</td>
</tr>
<tr>
<td>1. Potential for the study to fill critical gaps in evidence</td>
</tr>
<tr>
<td>2. Potential for the study findings to be adopted into clinical practice and improve delivery of care</td>
</tr>
<tr>
<td>APPROACH</td>
</tr>
<tr>
<td>3. Scientific merit (research design, analysis, and outcomes)</td>
</tr>
<tr>
<td>4. Investigator(s) and environment</td>
</tr>
<tr>
<td>PCORI-only Merit Review Criteria</td>
</tr>
<tr>
<td>PATIENT-CENTEREDNESS/ENGAGEMENT</td>
</tr>
<tr>
<td>5. Patient-centeredness</td>
</tr>
<tr>
<td>6. Patient and stakeholder engagement</td>
</tr>
</tbody>
</table>
Below are PCORI’s merit review criteria. PCORI’s merit review panels use these criteria during the preliminary and in-person review phases to evaluate and score all submitted applications, and to ensure consistency and fairness in how applications are evaluated.

**Criterion 1. Potential for the study to fill critical gaps in evidence:**
The application should address the following questions:

- Does the application convincingly describe the clinical burden?
- Does the application identify a critical gap in current knowledge as noted in systematic reviews, guideline development efforts, or previous research prioritizations?
- Does the application identify a critical gap in current knowledge, evidenced by inconsistency in clinical practice and decision making?
- Would research findings from the study have the potential to fill these evidence gaps?

**Criterion 2. Potential for the study findings to be adopted into clinical practice and improve delivery of care**
The application should describe how evidence generated from this study could be adopted into clinical practice and delivery of care by others. The application should also address the following questions:

- Does the application identify who will make the decision (i.e., the decision maker) or use (i.e., the end-user) the study findings (not the intervention) this study produces, such as local and national stakeholders?
- Does the application identify potential end-users of study findings—such as local and national stakeholders—and describe strategies to engage these end-users?
- Does the application provide information that supports a demand for this kind of a study from end-users?
- Would this study’s research findings have the potential to inform decision making for key stakeholders? If so, provide an example. How likely is it that positive findings could be reproduced by others, resulting in improvements in practice and patient outcomes? Identify the potential barriers that could hinder adoption of the intervention by others.
- Does the application describe a plan for how study findings will be disseminated beyond publication in peer-review journals and at national conferences?

**Criterion 3. Scientific merit (research design, analysis, and outcomes)**
The application should show sufficient technical merit in the research design to ensure that the study goals will be met. The application should also address the following questions:

- Does the application describe a clear conceptual framework anchored in background literature which informs the design, key variables, and relationship between interventions and outcomes being tested?
Does the Research Plan describe rigorous methods that demonstrate adherence to the PCORI Methodology Standards?

Is the overall study design justified?

Are the patient population and study setting appropriate for the proposed research question?

Does the application provide justification that the outcome measures are validated and appropriate for the population?

Are each of the comparators (e.g., active intervention arm and comparator arm) described clearly and well-justified? If “usual care” is one of the arms, is it adequately justified and will it be sufficiently measured?

Are the sample sizes and power estimates appropriate? Is the study design (e.g., cluster randomized design, RCT, or observational study) accounted for and is the anticipated effect size adequately justified?

Is the study plan feasible? Is the project timeline realistic, including specific scientific and engagement milestones? Is the strategy for recruiting participants feasible? Are assumptions about participant attrition realistic, and are plans to address patient or site attrition adequate?

**Criterion 4. Investigator(s) and environment**

This criterion should assess the appropriateness (e.g., qualifications and experience) of the investigator(s)/team and the environment’s capacity (e.g., resources, facilities, and equipment) to support the proposed project. It should not be an assessment of the institution’s quality.

The application should also address the following questions:

- How well-qualified are the PIs, collaborators, and other researchers to conduct the proposed activities? Is there evidence of sufficient clinical or statistical expertise (if applicable)?
- Does the investigator or co-investigator have demonstrated experience conducting projects of a similar size, scope, and complexity?
- If the project is collaborative or dual-PI, do the investigators have complementary and integrated expertise? Are the leadership, governance, and organizational structures appropriate for the project?
  - (Dual-PI option only) Does the Leadership Plan adequately describe and justify PI roles and areas of responsibility?
- Is the level of effort for each team member appropriate for successfully conducting the proposed work?
- Does the application describe adequate availability of and access to facilities and resources (including patient populations, samples, and collaborative arrangements) to carry out the proposed research?
- Is the institutional support appropriate for the proposed research?
Criterion 5. Patient-centeredness
The application should demonstrate that the study focuses on improving patient-centered outcomes and employs a patient-centered research design (i.e., a design informed or endorsed by patients). (Note: The study can be patient-centered even if the end-user is not the patient, as long as patients will benefit from the information.)

The application should also address the following questions:

- Does the application include a thorough description about which outcomes (both benefits and harms) are important to patients, and are those outcomes included in the study plan?
- Does the application provide information that indicates that closing the evidence gap is important to patients and other stakeholders?
- Are the interventions being compared in the study available to patients now, and are they the best options for comparison (including whether they would be chosen by patients and their healthcare providers for managing the condition being studied)?

Criterion 6. Patient and stakeholder engagement
The application should demonstrate the engagement of relevant patients and other stakeholders (e.g., patients, caregivers, clinicians, policy makers, hospitals and health systems, payers [insurance], purchasers [business], industry, researchers, and training institutions) in the conduct of the study. Quality of engagement should be evaluated based on scope, form, and frequency of patient and stakeholder involvement throughout the research process.

The application should also address the following questions:

- Does the application provide a well-justified description of how the research team incorporates stakeholder involvement? Does the study include the right individuals (e.g., researchers, patients, caregivers, clinicians, policy makers, and other healthcare system stakeholders) to ensure that the projects will be carried out successfully?
- Does the application show evidence of active engagement among scientists, patients, and other stakeholders throughout the research process (e.g., formulating questions, identifying outcomes, monitoring the study, disseminating, and implementing)? Is the frequency and level of patient and stakeholder involvement sufficient to support the study goals?
- Is the proposed Engagement Plan appropriate and tailored to the study?
- Are the roles and the decision-making authority of all study partners described clearly?
- Are the organizational structure and resources appropriate to engage patients and stakeholders throughout the project?

In-Person Review
During preliminary review, all administratively and scientifically compliant applications are evaluated and scored based on PCORI’s merit review criteria, including evaluation of adherence to the PCORI Methodology Standards. After PCORI completes the preliminary review, PCORI program staff members evaluate panel scores and critiques to identify a subset of applications for merit reviewers to discuss at
the in-person review meeting. Not all submitted applications move forward to in-person review.

During the in-person review, merit reviewers meet to discuss applications and to clarify further the merits of the proposed research. They also identify areas for improvement. Each application is re-scored based on the content of discussion. The Panel Chair and PCORI MRO lead the in-person panel meeting and ensure that all applications receive a fair and thorough review according to the standards outlined in the PFA.

Post-Panel Review

After the in-person meeting, PCORI program staff evaluate final merit review panel scores and comments, identify duplication or synergy among funded projects, and consider the fit of applications within the programmatic vision. Program staff members then recommend projects to a Selection Committee, which includes members of the Board. The Selection Committee considers recommendations and works with staff to identify a slate of applications for possible funding based on merit review scores, programmatic balance and fit, and PCORI’s strategic priorities. This slate is then proposed to the Board for consideration and approval.

In addition, PCORI evaluates applicant risk before issuing a PCORI award. Factors considered include financial stability, quality of management systems, audit findings, and past performance on PCORI awards (e.g., compliance with PCORI reporting requirements, conformance to PCORI terms and conditions on previous awards, and timely achievement of milestones). Based on the risk assessment, PCORI may impose special terms and conditions on awardees or withhold contract issuance until such business risks are mitigated. **PCORI will not award new contracts to current awardees with overdue reports (progress, interim, final, etc.) until the overdue reports have been submitted to PCORI.**

Summary Statements and Funding Recommendations

Summary statements are provided to applicants approximately two weeks before funding decisions are announced. **If an application progresses to in-person discussion,** the applicant will receive a summary statement inclusive of:

- In-person panel discussion notes
- Final average overall score
- Preliminary reviewer critiques
- Application quartile, which provides information for applicants to understand how they did relative to other discussed applications

Summary statements for applications that do not progress to in-person discussion include only the preliminary reviewer critiques.

Funding recommendations are made by identifying meritorious applications that fit the programmatic needs and that satisfactorily address the merit review criteria while adhering to the PCORI Methodology Standards. Programs also consider the funds allotted for the current funding announcement when deciding which applications to recommend to the Board for approval. Applicants to this current cycle’s PFA will receive summary statements in November 2017 and notification of the funding status of their
application no later than November 2017.